Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Citations 0
Editor's Correspondence
January 14, 2002

The Advantages of Using Non–HDL-C in the Diagnosis and Treatment of Dyslipidemia

Author Affiliations

Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002

Arch Intern Med. 2002;162(1):108-109. doi:

A high LDL-C level is associated with an increased risk for coronary heart disease. It is considered the main risk factor in the lipid profile and is the primary target of therapy.1 However, the estimation of LDL-C has significant limitations in some groups, such as in individuals with hypertriglyceridemia or mixed hyperlipidemia or even in normolipidemic individuals with diabetes mellitus.2 These limitations are explained by the abnormal composition of the triglyceride-rich lipoproteins found in these conditions, which is not considered in the Friedewald formula.3 Some of the limitations of LDL-C could be overcome by using non–HDL-C.4 The recent article by Cui and coworkers5 demonstrates that non–HDL-C is a stronger predictor of CVD death than LDL-C in data derived from the Lipid Research Clinics Program Follow-up Study. Indeed, LDL-C level was the weakest lipid predictor of CVD death in men and women.

First Page Preview View Large
First page PDF preview
First page PDF preview